Drugging Plk1: An Attractive Approach to Inhibit Androgen Receptor Signaling
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Gasimli K, Raab M, Becker S, Sanhaji M, Strebhardt K J Cancer. 2022; 13(3):728-743.
PMID: 35154442 PMC: 8824877. DOI: 10.7150/jca.66492.
Weiss G, Jameson G, Von Hoff D, Valsasina B, Davite C, Di Giulio C Invest New Drugs. 2017; 36(1):85-95.
PMID: 28726132 DOI: 10.1007/s10637-017-0491-7.
References
1.
Strebhardt K, Ullrich A
. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30.
DOI: 10.1038/nrc1841.
View
2.
Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E
. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun. 2011; 2:395.
PMC: 3144583.
DOI: 10.1038/ncomms1395.
View
3.
Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R
. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-82.
PMC: 4075966.
DOI: 10.1038/nature13229.
View
4.
Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S
. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate. 2013; 73(12):1352-63.
PMC: 3720713.
DOI: 10.1002/pros.22683.
View
5.
Raab M, Kramer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dotsch C
. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. Mol Oncol. 2014; 9(1):140-54.
PMC: 5528686.
DOI: 10.1016/j.molonc.2014.07.020.
View